NCT01090427 – A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the of Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasis (CADMUS) Posted on July 3, 2018 by tsuperadmin -
NCT01059773 – An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT) Posted on July 3, 2018 by tsuperadmin -
NCT01008995 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT00747344 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT00454584 – A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT00320216 – A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT00265122 – A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn’s Disease Posted on July 3, 2018 by tsuperadmin -
NCT00723528 – A Placebo-Controlled Double-Blind Comparative Study of CNTO1275 in Patients With Plaque Type Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT01550744 – A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a “Subject-tailored” Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT00267956 – A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Posted on January 29, 2018 by tsuperadmin -
The YODA Project